(4-氰基苄基硫代)乙酸 | 178270-52-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-氰基苄基硫代)乙酸
• 英文名称: (4-Cyanobenzylthio)acetic acid
• 英文别名: 2-{[(4-Cyanophenyl)methyl]sulfanyl}acetic acid；2-[(4-cyanophenyl)methylsulfanyl]acetic acid
• CAS: 178270-52-5
• 化学式: C₁₀H₉NO₂S
• mdl: MFCD01030701
• 分子量: 207.253
• InChiKey: YAPZRBCKDSHRQX-UHFFFAOYSA-N

物化性质

• 沸点：
  409.8±35.0 °C(Predicted)
• 密度：
  1.31±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  86.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (4-氰基苄基硫代)乙酸 在 双氧水 、 溶剂黄146 作用下， 反应 18.0h， 生成 4-cyanobenzylsulfonylacetic acid
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of (E)-Styrylbenzylsulfones as Novel Anticancer Agents

  摘要：

  Cell cycle progression is regulated by cyclins and cyclin-dependent kinases, which are formed at specific stages of the cell cycle and regulate the G1/S and G2/M phase transitions, employing a series of "checkpoints" governed by phosphorylation of their substrates. Tumor development is associated with the loss of these checkpoint controls, and this provides an approach for the development of therapeutic agents that can specifically target tumor cells. Here, we describe the synthesis and SAR of a novel group of cytotoxic molecules that selectively induce growth arrest of normal cells in the G1 phase while inducing a mitotic arrest of tumor cells resulting in selective killing of tumor cell populations with little or no effect on normal cell viability. The broad spectrum of antitumor activity in vitro and xenograft models, lack of in vivo toxicity, and drug resistance suggest potential for use of these agents in cancer therapy.

  DOI：

  10.1021/jm701077b
• 作为产物：
  描述：

  巯基乙酸 、 对氰基溴化苄 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 4.0h， 生成 (4-氰基苄基硫代)乙酸
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of (E)-Styrylbenzylsulfones as Novel Anticancer Agents

  摘要：

  Cell cycle progression is regulated by cyclins and cyclin-dependent kinases, which are formed at specific stages of the cell cycle and regulate the G1/S and G2/M phase transitions, employing a series of "checkpoints" governed by phosphorylation of their substrates. Tumor development is associated with the loss of these checkpoint controls, and this provides an approach for the development of therapeutic agents that can specifically target tumor cells. Here, we describe the synthesis and SAR of a novel group of cytotoxic molecules that selectively induce growth arrest of normal cells in the G1 phase while inducing a mitotic arrest of tumor cells resulting in selective killing of tumor cell populations with little or no effect on normal cell viability. The broad spectrum of antitumor activity in vitro and xenograft models, lack of in vivo toxicity, and drug resistance suggest potential for use of these agents in cancer therapy.

  DOI：

  10.1021/jm701077b

文献信息

• Substituted styryl benzylsulfones for treating proliferative disorders
  申请人：——

  公开号：US20020115643A1

  公开（公告）日：2002-08-22

  Styryl benzylsulfones of formula I are useful as antiproliferative agents, including, for example, anticancer agents: 1 wherein (a) (i) at least three of R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and (ii) R 6 , R 7 , R 8 , R 9 and R 10 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; or (b) (i) at least three of R 6 , R 7 , R 8 , R 9 and R 10 are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R 6 , R 7 , R 8 , R 9 and R 10 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and (ii) R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; or a pharmaceutically acceptable salt thereof.

  式I的苯基砜基苯乙烯是有用的抗增殖剂，包括例如抗癌剂：其中 (a) (i) R1、R2、R3、R4和R5中至少三个独立地选自卤素、C1-C6烷基、C1-C6烷氧基、硝基、氰基、羧基、羟基、膦酸基、氨基、磺胺基、乙酰氧基、二甲胺基(C2-C6烷氧基)和三氟甲基的群组，以及所述的R1、R2、R3、R4和R5的余下部分独立地选自氢、卤素、C1-C6烷基、C1-C6烷氧基、硝基、氰基、羧基、羟基、膦酸基、氨基、磺胺基、乙酰氧基、二甲胺基(C2-C6烷氧基)和三氟甲基的群组；和 (ii) R6、R7、R8、R9和R10独立地选自氢、卤素、C1-C6烷基、C1-C6烷氧基、硝基、氰基、羧基、羟基、膦酸基、氨基、磺胺基、乙酰氧基、二甲胺基(C2-C6烷氧基)和三氟甲基的群组；或 (b) (i) R6、R7、R8、R9和R10中至少三个独立地选自卤素、C1-C6烷基、C1-C6烷氧基、硝基、氰基、羧基、羟基、膦酸基、氨基、磺胺基、乙酰氧基、二甲胺基(C2-C6烷氧基)和三氟甲基的群组，以及所述的R6、R7、R8、R9和R10的余下部分独立地选自氢、卤素、C1-C6烷基、C1-C6烷氧基、硝基、氰基、羧基、羟基、膦酸基、氨基、磺胺基、乙酰氧基、二甲胺基(C2-C6烷氧基)和三氟甲基的群组；和 (ii) R1、R2、R3、R4和R5独立地选自氢、卤素、C1-C6烷基、C1-C6烷氧基、硝基、氰基、羧基、羟基、膦酸基、氨基、磺胺基、乙酰氧基、二甲胺基(C2-C6烷氧基)和三氟甲基的群组；或其药学上可接受的盐。
• Inhibitors of farnesyl-protein transferase
  申请人：Merck & Co., Inc.

  公开号：US05585359A1

  公开（公告）日：1996-12-17

  The present invention comprises analogs of the CAAX motif of the protein Ras that is modified by farnesylation in vivo. These CAAX analogs inhibit the farnesylation of Ras. Furthermore, these CAAX analogues differ from those previously described as inhibitors of Ras farnesyl transferase in that they do not have a thiol moiety. The lack of the thiol offers unique advantages in terms of improved pharmacokinetic behavior in animals, prevention of thiol-dependent chemical reactions, such as rapid autoxidation and disulfide formation with endogenous thiols, and reduced systemic toxicity. Further contained in this invention are chemotherapeutic compositions containing these farnesyl transferase inhibitors and methods for their production.

  该发明涵盖了蛋白质Ras的CAAX基序的类似物，该基序在体内通过法尼酰化进行修饰。这些CAAX类似物抑制了Ras的法尼酰化。此外，这些CAAX类似物与先前描述的抑制Ras法尼酰基转移酶的类似物不同，因为它们不含硫醇基团。缺乏硫醇基团在改善动物的药代动力学行为、预防硫醇依赖的化学反应（如快速自氧化和与内源硫醇形成二硫键）以及减少全身毒性方面具有独特优势。该发明还包括含有这些法尼酰基转移酶抑制剂的化疗组合物和其生产方法。
• Substituted benzylthioacetic acids and esters
  申请人：——

  公开号：US20030036536A1

  公开（公告）日：2003-02-20

  Styryl benzylsulfones of formula I are useful as antiproliferative agents, including, for example, anticancer agents: 1 wherein R 1 through R 10 are defined herein; or a pharmaceutically acceptable salt thereof.

  式I中的苯基磺酰苯基烷基化合物是一种有用的抗增殖剂，包括例如抗癌剂：1其中R1至R10在此定义；或其药学上可接受的盐。
• Potent, non-thiol inhibitors of farnesyltransferase
  作者：Michael J. Breslin、S.Jane deSolms、Elizabeth A. Giuliani、Gerald E. Stokker、Samuel L. Graham、David L. Pompliano、Scott D. Mosser、Kelly A. Hamilton、John H. Hutchinson

  DOI：10.1016/s0960-894x(98)00586-1

  日期：1998.12

  The structure-activity relationship of a series of non-thiol CaaX analogs, which are inhibitors of farnesyltransferase, is described. These inhibitors contain a substituted phenyl group at the N terminus, which may occupy a novel binding domain on the Ras protein. (C) 1998 Elsevier Science Ltd. All rights reserved.
• INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE
  申请人：Merck & Co., Inc.

  公开号：EP0783318A1

  公开（公告）日：1997-07-16